Thomas Uslar

Santiago, RM, Chile

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months.

Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: July 22, 2026

Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study.

Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study.

Journal: European journal of internal medicine

Published: March 25, 2026

Driving hypertension: non-classic apparent mineralocorticoid excess.

Driving hypertension: non-classic apparent mineralocorticoid excess.

Journal: Nature reviews. Endocrinology

Published: November 12, 2025

Exogenous corticosteroid-induced modulation of RAAS: potential implications for septic shock biomarker analysis.

Exogenous corticosteroid-induced modulation of RAAS: potential implications for septic shock biomarker analysis.

Journal: Annals of intensive care

Published: April 08, 2025

Real-world outcomes of finerenone in primary aldosteronism.

Real-world outcomes of finerenone in primary aldosteronism.

Journal: European journal of endocrinology

Published: February 25, 2025

A global real-world study assessing total time to adrenalectomy in primary aldosteronism.

A global real-world study assessing total time to adrenalectomy in primary aldosteronism.

Journal: European journal of endocrinology

Published: February 12, 2025

Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case.

Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case.

Journal: American journal of hypertension

Published: November 26, 2024

Genotype-specific neoplastic risk profiles in patients with VHL disease.

Genotype-specific neoplastic risk profiles in patients with VHL disease.

Journal: Endocrine-related cancer

Published: October 08, 2024

Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas.

Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas.

Journal: Therapeutic advances in medical oncology

Published: September 04, 2024

Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines.

Progressive 11β-Hydroxysteroid Dehydrogenase Type 2 Insufficiency as Kidney Function Declines.

Journal: The Journal of clinical endocrinology and metabolism

Published: July 16, 2024

Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.

Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.

Journal: The lancet. Diabetes & endocrinology

Published: May 29, 2024

Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.

Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.

Journal: Endocrine

Published: March 28, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026